TP53 and cancer: Nowadays, genome-wide tumor sequencing studies have firmly established that p53’s tumor-suppressive function is abrogated in approximately 50% of all cancer cells, mostly because of missense mutations affecting up to 80% of the residues within its DNA-binding core domain [11,12].